ALK and non-small cell lung carcinoma: In comparison with crizotinib, the second-generation ALK TKI alectinib shows improved specificity for ALK and superior efficacy against EML-ALK harboring the crizotinib-resistant mutation L1196M, which is detected in patients with crizotinib-relapsed/refractory NSCLC [10].